Cargando…

Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost

Introduction. The topical medications containing benzalkonium chloride (BAK) as preservative is known to induce corneal toxicity and ocular surface disease (OSD) in glaucoma patients. Newer preservatives like SofZia or polyquaternium-1 (Polyquad) have been developed to replace BAK in many medication...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Suresh, Singh, Tanu, Ichhpujani, Parul, Vohra, Sanchi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Romanian Society of Ophthalmology 2019
Materias:	General Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820501/ https://www.ncbi.nlm.nih.gov/pubmed/31687627

Ejemplares similares

Correlation of Ocular Surface Disease and Quality of Life in Indian Glaucoma Patients: BAC-preserved versus BAC-free Travoprost
por: Kumar, Suresh, et al.
Publicado: (2020)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
por: Katz, Gregory, et al.
Publicado: (2010)

Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension
por: Mirza, Sophia K, et al.
Publicado: (2010)

First experience with BAK-free travoprost 0.004% in topical glaucoma medication
por: Gado, Ahmed Salah, et al.
Publicado: (2012)

Generic benzalkonium chloride‐preserved travoprost eye drops are not identical to the branded polyquarternium‐1‐preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties
por: Hedengran, Anne, et al.
Publicado: (2022)

Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
por: Inoue, Kenji, et al.
Publicado: (2012)

Travoprost in the management of open-angle glaucoma and ocular hypertension
por: Denis, Philippe, et al.
Publicado: (2007)

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
por: Henry, J Charles, et al.
Publicado: (2008)

Travoprost Induced Granulomatous Anterior Uveitis
por: Chiam, Patrick
Publicado: (2011)

Efficacy of travoprost for the treatment of patients with glaucoma
por: Zhang, Xiu-Li, et al.
Publicado: (2019)

Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system
por: Ryan, Gerard, et al.
Publicado: (2011)

Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
por: Kozobolis, Vassilios, et al.
Publicado: (2018)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
por: Godfrey, David A, et al.
Publicado: (2009)

Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients
por: El Hajj Moussa, Wissam Georges, et al.
Publicado: (2018)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Miyashiro, Michael J, et al.
Publicado: (2010)

The diurnal and nocturnal effects of travoprost in normal-tension glaucoma
por: Seibold, Leonard K, et al.
Publicado: (2014)

Hypertrichosis and Hyperpigmentation in the Periocular Area Associated with Travoprost Treatment
por: Lee, Hae-Eul, et al.
Publicado: (2015)

Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
por: Wadhwani, Meenakshi, et al.
Publicado: (2016)

Travoprost with sofZia® preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects
por: Mizoue, Shiro, et al.
Publicado: (2014)

Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
por: García-Feijoo, Julian, et al.
Publicado: (2016)

Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
por: Suzuki, Emilio Rintaro, et al.
Publicado: (2010)

Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure
por: Quaranta, Luciano, et al.
Publicado: (2015)

Travoprost Liquid Nanocrystals: An Innovative Armamentarium for Effective Glaucoma Therapy
por: El-Gendy, Mohamed A., et al.
Publicado: (2023)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Teus, Miguel A, et al.
Publicado: (2009)

Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
por: Lerner, S Fabián, et al.
Publicado: (2019)

Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma
por: Nomura, Yuya, et al.
Publicado: (2010)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Lafuma, Antoine, et al.
Publicado: (2011)

Effect of benzalkonium chloride–free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study
por: Lopes, Joao F., et al.
Publicado: (2015)

Comparing the effect of benzalkonium chloride-preserved, polyquad-preserved, and preservative-free prostaglandin analogue eye drops on cultured human conjunctival goblet cells
por: Hedengran, Anne, et al.
Publicado: (2024)

Corneal Alterations Induced by Topical Application of Commercial Latanoprost, Travoprost and Bimatoprost in Rabbit
por: Chen, Wensheng, et al.
Publicado: (2014)

Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients
por: Cai, Ziyan, et al.
Publicado: (2021)

Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy
por: Jordão, Marcelo Lopes da Silva, et al.
Publicado: (2014)

Efficacy And Safety Of Travoprost Versus Timolol To Treat Early-Onset Ocular Hypertension Secondary To Vitrectomy: A Randomized Trial
por: Fang, Yuan, et al.
Publicado: (2019)

Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%
por: Gross, Ronald L, et al.
Publicado: (2007)

Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells
por: Ammar, David A., et al.
Publicado: (2011)

Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
por: Dubiner, Harvey B, et al.
Publicado: (2012)

Correction: Corneal Alterations Induced by Topical Application of Commercial Latanoprost, Travoprost and Bimatoprost in Rabbit
Publicado: (2014)

Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma
por: Naito, Tomoko, et al.
Publicado: (2016)

Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population
por: Perera, Shamira A, et al.
Publicado: (2016)

The effects of selective laser trabeculoplasty and travoprost on circadian intraocular pressure fluctuations: A randomized clinical trial
por: Kiddee, Weerawat, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kirqqc3h20gqnffk5ee5omconn